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Summary. Studies of human prostate carcinoma (PCA) 
have been hampered by only a few cell systems from 
already-metastatic human disease. We have developed a 
novel cell system by using tissue cultured CWR22R 
cells from a xenograft of a primary tumor from a human 
patient. These cells were transfected with the bacterial 
lacZ gene to maximize their detection during 
progression and metastasis in nude mice. LZ-CWR22R 
cells are extremely stable for lacZ expression over 25 
passages and metastasize to lung, liver, and bone from 
the subcutis - major sites of metastasis of the human 
disease. A matrigel vehicle facilitated development of 
primary tumors and micrometastases in al1 organs. While 
some micrometastases developed into overt metastases, 
others remained as micrometastases for long periods of 
time, possibly providing a model of latency of metastatic 
disease. An experimental metastasis model (tail vein 
injection) also generated micrometastases in lung, liver, 
and bone with differing kinetics of formation and 
stability. Serial sections of many individual lung 
micrometastases within one hour of injection indicated 
considerable heterogeneity in cellular composition (from 
1 to 19 cells/site) while liver sites at later times were 
comprised of only 1 or 2 cells (the size of bone sites 
were comparable to those of liver). By combining use of 
these histochemically-tagged PCA cell systems with 
high resolution molecular analyses (laser-capture 
microdissection), it will now be possible to analyze gene 
expression patterns characteristic of micrometastases 
developing in severa1 different organs. 
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lntroduction and Background 
Animal models of human prostate carcinoma have 
principally used DU145, PC3, or LNCaP cell systems 
(Pretlow et al., 1994; Zhau et al., 1996; Lalani et al., 
1997; Rubio et al., 1998; Yang et al., 1999). However, 
these cells are derived from metastases of human 
patients and therefore are already-selected metastatic 
variants. This obviates any analyses of how metastatic 
variants arise during formation of human primary tumors 
of prostate carcinoma (PCA). 
New cell systems became available with 
development of severa1 xenografts of primary tumors 
from human PCA patients passed in athymic nude mice 
(Pretlow et al., 1993; Wainstein et al., 1994; Cheng et 
al., 1996). One of these, CWR22R (Nagabhushan et al., 
1996), was particularly notable because (a) it was 
metastatic to the lung in nude mice as a xenograft and 
(b) a tissue cultured cell line was developed from this 
xenograft that was also tumorigenic in nude mice 
(Sramkoski et al., 1999). The CWR22R cell line also 
shares many other properties characteristic of prostate 
cancer cells and the xenograft of origin (Sramkoski et 
al., 1999). 
Our laboratory has had considerable success in 
analyzing the earliest events  in progression and 
metastasis by transfecting a histochemical marker gene, 
such as bacterial IacZ or human placental alkaline 
phosphatase genes, into fibrosarcoma (Lin et al., 
1990a,b, 1992) or neuroblastoma tumor cells (Kleinman 
et al., 1994) and tracking single tumor cells in any organ 
of nude mice via histochemical reactivity. These studies 
have been reviewed previously by us (Lin and Culp, 
1992a,b; Culp et al., 1999) and others (Kruger et al., 
1999). 
We have now generated lacZ transfectants of the 
tissue cultured CWR22R PCA cell line to pursue 
progression and metastasis analyses in nude mice (Culp 
et al., 1998). Severa1 transfectant clones of CWR22R 
demonstrated highly unstable or only moderately stable 
expression of the lacZ gene. However, clone H was 
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highly unusual (Culp et al., 1998). Its expression was 
extremely stable in cultured cell populations for >25 
passages (>85% of the cells expressing it). This stability 
exceeded that of our previous analyses of many 
transfectant clones of fibrosarcoma and neuroblastoma 
(Lin and Culp, 1992a; Kleinman et al., 1994). Whether 
this is a novel property of this particular clone or is a 
general property of human prostate cancer cells derived 
from primary tumors will require analyses of many more 
xenografts and their complementary tissue cultured 
populations. 
The tumorigenic properties of this LZ-CWR22R 
clone H cell line have been analyzed by Holleran et al. 
(2000). These and additional studies are reviewed below. 
Primary tumor formation 
A critical issue was whether LZ-CWR22R cells 
formed tumors in the subcutis of nude mice as displayed 
by the original xenograft (Nagabhushan et al., 1996) and 
the original cell line (Sramkoski et al., 1999). This was 
the case under two different sets of conditions (Holleran 
et al., 2000). Animals injected with 1-5x10~ cells in a 
PBS vehicle yielded tumors 15-40% of the time over a 
lengthy period of time. In contrast, 100% of the animals 
developed tumors within 3-4 weeks when a matrigel 
vehicle was used for injection. This suggests that 
stabilization of these PCA tumor cells on a suitable 
extracellular matrix in the subcutis may be limiting for 
successful outgrowth. We had previously documented 
formation of the earliest primary tumors of fibrosarcoma 
(O'Connor and Culp, 1994) and neuroblastoma 
(Kleinman et al., 1994) tumor cel ls  by tracking 
histochemically-stainable tumor cells in the subcutis at 
very high resolution within hours and days of injection. 
This type of analysis should be particularly revealing for 
LZ-CWR22R cells. By determining their fate in those 
first hours and days of residence in the subcutis, we can 
determine whether cells are cleared far more effectively 
from the subcutis when matrigel is not used or whether 
tumor cells persist in both cases but only with matrigel 
does outgrowth occur. 
Another critical issue was the X-gal-stainability of 
tumors as they developed into large masses (Holleran et 
al. ,  2000). If tumors remained highly stainable 
throughout their development, then we could be 
confident of maximizing the discovery of 
micrometastases in any organ of the animal over lengthy 
periods. Indeed, this was the case (Holleran et al., 2000). 
Small or large tumors in the subcutis, whether cells were 
injected with PBS or matrigel vehicles, revealed 
excellent stainability with X-gal. Every primary tumor 
analyzed displayed excellent stainability. This was also 
true when tumors were cut into large segments and then 
these segments X-gal-stained, indicating that lacZ- 
nonexpressing cells were not clonally dominating at the 
interior regions of the tumor and that expressability 
persisted throughout the architecture of the large tumor 
mass. 
Spontaneous micrometastasis to multiple organs 
While the original CWR22R xenograft was shown to 
metastasize to the lung but not to other organs 
(Nagabhushan et al., 1996), it was essential to determine 
whether the clonal population of LZ-CWR22R cells 
would also be metastatic to the lung andlor other organs. 
Our confidence in the sensitivity of this system was 
reinforced by the excellent and persistent X-gal staining 
of al1 primary tumors, as described above, but also by 
our previous analyses demonstrating our ability to detect 
single tumor cells in virtually any organ of the animal 
using histochemical reactivity (Lin and Culp, 1992a,b; 
Culp et al., 1998, 1999). 
In animals injected s.c. with cells in a PBS vehicle 
and eventually developing primary tumors, spontaneous 
micrometastases were observed in the lungs of al1 these 
animals (Holleran et al., 2000). This was not the case for 
animals that did not yield sizable primary tumors, 
indicating that metastatic variants were indeed arising as 
subpopulations of the primary tumor. At lower 
frequencies, some animals also displayed 
micrometastases in liver, bone, kidney, and brain. These 
frequencies are enumerated as follows for PBS-injected 
cells: lung >>liver=bone (approx. 50%)>>kidney=brain 
(approx. 10%). 
In animals injected with cells in a matrigel vehicle, 
the pattern of metastasis to multiple organs was 
qualitatively similar to those animals injected with PBS- 
borne cells. However, the quantitative relationships 
differed significantly (in addition to the excellent 
frequency of primary tumor formation reviewed above) 
[Holleran et al., 20001. First, al1 animals developed 
micrometastases in their lungs - most animals with the 
number of sites comparable to PBS-injected cells but a 
few animals had a large number of lung 
micrometastases. Second, a higher frequency of bone 
micrometastasis was observed with matrigel-injected 
cells while the frequencies of liver and kidney sites were 
comparable. These frequencies are as follows: lung > 
bone (60%) > liver (20%) >> kidney or brain. This 
would indicate that the extracellular matrix provided by 
matrigel provides differing opportunities for selection of 
metastatic variants to bone and liver. This important 
finding should be addressed mechanistically with 
additional experiments. 
Examples of spontaneous micrometastases are 
shown in Figs. 1, 2. A lung micrometastasis at fairly 
high magnification is shown in Fig. 1A while low 
magnification images of two liver micrometastases are 
illustrated in Fig. 1B (a third one is visible at the upper 
left in this panel). Kidney micrometastases (one with a 
highly unusual linear array of cells) are shown in Fig. 
1 C. 
Particularly notable in our studies was the discovery 
that these cells could spontaneously metastasize to bone, 
a primary site of the human disease and a difficult target 
for spontaneous metastasis, except by using already- 
bone-metastatic PC3 cells (Lalani et al., 1997; Wu et al., 
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Fig. 1. Micrometastasis to multiple organs with i, ,,.,. . ~f U-CWR22R cells in a rnatrigel vehicle. Matrigel-suspended clone H cells were injected S.C. 
into nude mice. When the primary tumors had become large, anirnals were sacrificed and rnany organs were excised, fixed, and X-gal-stained to 
evaluate development of rnicrornetastases. A. A lung micrometastasis (srnall arrow) at 44 days post-injection. x 102. B. Liver rnicrometastases (small 
arrows) at 72 days post-injection. x 34. C. Kidney rnicrornetastases (small arrows) at 44 days post-injection. x 17. raken from Holleran et al., 2000, 
with perrnission.] 
Flg. 2. Micrometastasis to bone. Clone H cells were injected S.C. in either PBS or rnatrigel vehicles. When primary tumors had becorne large, the 
anirnals were sacrificed for excision of many bones, followed by bone fixation and X-gal staining. A. Micrometastases (srnall amws) in the long bone of 
the leg 17 days post-PBS-injection. x 42. B. Micrometastases (srnall arrow) along the spinal column 113 days post-PBS-injection. x 13. C. 
Micrornetastases (small arrowheads) along the spinal colurnn 44 days post-rnatrigel-injection. x 34. raken from Holleran et al., 2000, with permission.] 
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1998; Boyce et al., 1999; Koeneman et al., 1999; Lange 
and Vessella, 1999; Yang et al., 1999). Fig. 2A illustrates 
two micrometastases in the long bone of the leg under 
conditions where background staining by X-gal is 
minimized. Spinal column micrometastases are shown in 
Fig. 2B,C. There is some evidence (e.g., Jacob et al., 
1999) that bone-recognizing adhesion protein, 
osteonectin, may be playing an important role in 
establishment of tumor sites in bone. It will now be 
important to screen for the participation of osteonectin 
and a variety of other adhesion ligands and their 
receptors to evaluate any critica1 participation in 
establishing prostate carcinoma micrometastases in 
various bone sites of the animal. 
A highly remarkable aspect of these studies is the 
consistent metastasis of LZ-CWR22R cells to lung, liver, 
and bone. These three sites are the most common targets 
of the human disease process and offer the greatest 
difficulty in clinically treating metastatic disease in 
patients. Therefore, this cell model offers an excellent 
example for dissecting the gene- and cell-regulatory 
events that make prostate carcinoma such a devastating 
disease. 
Outgrowth into overt metastases 
These analyses also addressed whether 
micrometastases could grow out into overt metastases in 
these various organs. Micrometastases were unstable in 
the brain and kidney and eventually disappeared by 
unknown mechanisms. In contrast, micrometastases in 
the lung persisted over severa1 months of animal 
observation as small foci. Rarely were overt metastases 
developing in the lungs of animals, indicating that this 
environment was not suitable for aggressive cell division 
of these populations while it was conducive for cells 
persisting at these sites for long periods of time (Tarin 
and Price, 1981). Severa1 experimental approaches can 
now be used to determine how outgrowth of lung 
metastases could be facilitated by environmental cues. 
In contrast, overt metastases were observed in the 
liver. This is particularly notable because the lung was 
populated with a large number of micrometastases while 
the liver was populated with very few. Therefore, the 
"specific activity" of outgrowth of liver-selected tumor 
populations was very high. An example of a large liver 
metastasis is shown in Fig. 3. This tumor displayed 
excellent X-gal stainability after a lengthy period of 
outgrowth (possibly as long as 65 days). This again 
indicates the persistente of expression of the lacZ gene 
even when selection pressures are very high. 
Androgen-relatedness for U-CWR22R cells 
These initial studies of a reporter gene-tagged PCA 
cell system led to some additional and important 
experiments. Those of Holleran et al. (2000) were 
performed in young male nude mice without androgen 
supplementation. These animals have very low levels of 
androgen in their circulation s o  that these initial 
experiments fail to address any androgen-relatedness of 
tumor progression and metastasis in this model. Clearly, 
androgen does regulate to some extent the fate of 
primary tumor development in humans and the evolution 
of metastatic variants (Pretlow et al., 1994; Zhau et al., 
1996; Lalani et al., 1997; Boyce et al., 1999; Koeneman 
et al., 1999; Lange and Vessella, 1999). 
To further test the significanceJinsignificance of 
androgen in this system, female mice or male mice in 
which testosterone pellets were implanted S.C. were 
evaluated after s.c. injection of tumor cells (J.L. Holleran 
& L.A. Culp, unpublished data). In both cases, matrigel 
was used as a vehicle to maximize efficiency of primarv 
Flg. 3. Overt metastasis in liver. LZ-CWR22R clone H cells were 
injected S.C. in PBS. When primary tumors had become large (in this 
case, 65 days post-injection), animals were sacrificed for excision of 
many interna1 organs, followed by their fixation and X-gal staining. A 
large liver metastasis (large arrow) was developing, staining throughout 
for lacZ expression. x 13. r aken  from Holleran et al., 2000, with 
permission.] 
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tumor formation and animals were observed for as long 
as six months. 
For female mice, primary tumor formation occurred 
at a lower frequency (20% of animals never developed 
them) and with a longer latency. Micrometastases were 
obsewed in al1 lungs of tumor-bearing animals but at a 
lower frequency than the experiments described above. 
Only 2/15 animals displayed bone micrometastases and 
no micrometastases were observed in any other organs, 
particularly liver. 
In contrast, male mice supplemented with 
testosterone pellets displayed a latency of primary tumor 
formation comparable to unsupplemented animals. Al1 
animals developed large primary tumors and they 
displayed an elevated frequency of micrometastases in 
liver and bone, as well as a much greater number of sites 
in the lungs. These experiments taken together indicate 
that testosterone is not absolutely critica1 to demonstrate 
micrometastasis to some organs but that it does elevate 
the efficiency of the selection process to other organs as 
well as increase the efficiency of primary tumor 
formation (J.L. Holleran & L.A. Culp, unpublished 
data). 
Experimental metastasis model using U-CWR22R 
cells 
The ability of LZ-CWR22R cells to spontaneously 
metastasize to lung, liver, and bone during one cycle of 
primary tumor outgrowth led us to question the origin of 
these metastatic variants. Were they present in the tissue 
cultured cell population already or were they only 
selected after lengthy outgrowth of the primary tumor in 
the subcutis? One approach for addressing these issues is 
the experimental metastasis model in which cells are 
injected into the tail veins of nude mice to test their 
ability to colonize one or more target organs (Fisher and 
Fisher, 1967; Fidler et al., 1978; Fidler and Hart, 1982; 
Kawaguchi and Nakamura, 1986; Fornabaio et al., 1988; 
Fidler and Ellis, 1994). This route obviates any 
participation of selection in the primary tumor and 
determines whether subsets of cells in the cultured 
population are competent for invading and colonizing 
specific organs. This approach was used successfully by 
our laboratory to demonstrate the importance of cell 
surface CD44s in fibrosarcoma colonization of the lung 
(Kogerman et al., 1997). 
These experiments become quantitative when 
individual tumor cells can be tracked in target organs 
minutes, hours, and days after injection - e.g., 
radiolabeled cells (Fisher and Fisher, 1967; Fidler, 1970) 
or melanin-producing melanoma cells (Fidler and Hart, 
1982). In our case, expression of lacZ has been ideal for 
these purposes (Lin et al., 1990b; Lin and Culp, 1992a,b; 
Culp et al., 1998, 1999); in both fibrosarcoma and 
neuroblastoma (Kleinman et al., 1994) systems, we 
demonstrated that cultured cells injected into tail veins 
could only populate the lung and no other organs. 
This approach has now been adapted to our LZ- 
CWR22R cell system (J.L. Holleran, C.J. Miller, N.L. 
Edgehouse, T.P. Pretlow and L.A. Culp, 2001, submitted 
for publication). Minutes after tail vein injection, LZ- 
CWR22R cells were colonizing the lung. While 
measures were taken to verify that a single-cell 
suspension was being injected (verified by plating them 
into tissue culture dishes at the same time), it appeared 
that the sizes of lung sites were quite heterogeneous. The 
number of these experimental micrometastases 
maximized during 1-2 hours after injection but were 
virtually al1 cleared from the lungs within 24 hours. This 
contrasts with lacZ-tagged fibrosarcoma cells whereby 
1-2% of the sites persisted in the lung for many days and 
weeks after injection (Lin et al., 1990b; Lin and Culp, 
1992a,b). 
~xperimental micrometastases were also observed in 
the liver and bones of these animal at a lower frequency 
and at a later time point (J.L. Hol1eran;C.J. Miller, N.L. 
Edgehouse, T.P. Pretlow and L.A. Culp, 2001, submitted 
for publication). However, these sites were much smaller 
and of a uniform size indicating homogeneity in their 
initial formation. These sites persisted for as long as one 
week before being cleared from the organ. At a lower 
frequency some sites were also observed in kidney and 
brain. 
Serlal sectionlng of individual micrometastases 
To date no laboratory has addressed the cellular 
complexity of individual micrometastases soon after 
they have formed. One reason may have been the lack of 
a suitably sensitive marker to identify individual cells in 
4-5 pm thick sections. Such an analysis was undertaken 
in our model with lung sites (J.L. Holleran, C.J. Miller, 
N.L. Edgehouse, T.P. Pretlow and L.A. Culp, 2001, 
submitted for publication). At the 15 minute time point, 
serial sections were made of X-gal-stainedlneutral-red- 
counterstained lungs and .22 individual rnicrometastases 
enumerated for the number of cells per site. Most sites 
contained 1 to as many as 5 cells per site. However, a 
small proportion of sites contained more cells - as many 
as 19 cells in one case. Since these cells have not had 
sufficient time to divide, this survey verifies the size 
heterogeneity of sites in the lung directly as a 
consequence of their formation. An example is provided 
in Fig. 4 in which a 2-cell site can be observed across 3 
adjacent sections; sections adjoining these failed to 
reveal any stained tumor cells. In a few rare cases, tumor 
cells could be visualized at this time point still bound to 
the endothelium of the small blood vessels of the lung. 
These data raise question as to how this 
heterogeneity in lung sites arises. l b o  different models 
can be suggested to explain these findings, either of 
which will require more sophisticated experiments to 
address. First, tumor cells may aggregate into clumps of 
varying size once they are in the animal's blood strearn. 
Alternatively, cells may circulate in the blood singly and 
then "home" to specific sites in the small blood vessels 
of the lung where "pioneering tumor cells" have opened 
Flg. 4. Serial sections of a single rnicrornetastasis. 
Clone H tumor cells were injected into the tail vein 
of an athymic nude rnouse. At 30 minutes post- 
injection, the rnouse was sacrificed; the lungs were 
excised, fixed, and X-gal-stained. Pieces of lung 
were cut out of the tissue, one of which was 
serially sectioned to give the sections (A-C) shown 
here harboring only one rnicrornetastasis. Sections 
were 5 prn thick. Note that this rnicrornetastasis is 
cornprised of 2 cells (arrows). Several sections on 
either side of these three sections did not reveal 
any tumor cells. x 65 
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a route into lung tissue architecture. 
A similar analysis was made of liver 
micrometastases (J.L. Holleran, C.J. Miller, N.L. 
Edgehouse, T.P. Pretlow and L.A. Culp, 2001, submitted 
for publication). However, there are far fewer of these 
sites and only 8 individual sites could be dissected by 
this approach. In al1 cases, only 1 or 2 cells could be 
identified in these 8 sites. This is consistent with the 
relative homogeneity of liver sites andlor their smaller 
sizes compared to many of the lung sites. Although bone 
micrometastases have not yet been serially sectioned, 
their sizes are also quite small and similar to those of 
liver, suggesting that only 1 or 2 cells comprise these 
sites. 
Major flndings from these studies and future 
directions 
Several conclusions can be drawn from this 
experimental metastasis analysis of LZ-CWR22R, 
particularly when compared to the spontaneous 
metastasis studies deciphered by Holleran et al. (2000). 
First, the tissue cultured population contains subsets of 
cells that are competent for establishing transient 
rnicrometastases in lung, liver, and bone without going 
through any selection process in a primary tumor. 
Whether these cell types are identical to those that form 
spontaneous micrometastases from the subcutis-borne 
primary tumor remains to be tested. This may be 
unlikely given the instability of the experimental 
micrometastases versus the relative stability of the 
micrometastases in these same organs based on selection 
from a subcutis-localized primary tumor. 
It will now be possible to do gene-array analysis of 
both spontaneous and experimental micrometastases 
(individual ones at that) to test their gene expression 
patterns. Laser-capture microdissection (Emmert-Buck 
et al., 1996; Schutze and Lahr, 1998; Simone et al., 
1998) can be used to capture these very small 
micrometastases from X-gal-stained lung, liver, and 
bone for several comparisons: (a) among sites from the 
three target organs to test for organ specificity in gene 
expression; (b) between spontaneous and experimental 
micrometastases in one organ to determine if the same 
cell subpopulations are being selected; (c) between 
micrometastases forming in liver or bone from primary 
tumors developing in the subcutis (ectopic injection) 
versus the prostate gland (orthotopic injection) to 
determine if routing selects for different cell types; and 
(d) between micrometastases forming in lung after 
injection of LZ-CWR22R cells versus lacZ-tagged 
fibrosarcoma cells to determine any common gene 
activities shared by these two different tumor classes. 
Another important contrast in these studies is the 
marked homogeneity of micrometastases in liver and 
bone with only single or doublet cells in each site and 
the heterogeneity in size of lung sites. Since the lung is 
the first organ encountered after tail vein injection, this 
may indicate that any aggregation in the blood leads to 
"filtration" of aggregates once in the lung circulation. 
Subsequent circulation to the liver and skeletal sites 
would only include single cells. However, this does not 
exclude the possibility that lung sites for tumor cell 
colonization are intrinsically different from sites in liver 
and bone by permitting many cells to "collect" at 
specialized lung microvasculature sites for whatever 
reasons (Blood and Zetter, 1990; Folkman, 1995). 
Perhaps the best way to address these questions is to 
inject single-cell suspensions of tumor cells into other 
blood vessels of the animal and monitor the size and 
cellular composition of experimental micrometastases at 
the first organs encountered versus those at distant 
organs. Other experimental approaches may also be 
useful - e.g., injecting various dilutions of tumor cells to 
determine if cell concentration plays any role, injecting 
two different cell types tagged with different 
histochemical marker genes to determine cellular 
complexity (Lin et al., 1993), and performing sequential 
injections to determine if there are a limited number of 
lung sites that are "saturable". 
Comparisons of our previous studies with lacZ- 
tagged fibrosarcoma cells (Lin et al., 1990b; Lin and 
Culp, 1992a,b) and these LZ-CWR22R PCA cells 
(Holleran et al., 2000) lead to severa1 other hypotheses. 
Why are LZ-CWR22R cells cleared so completely from 
the lungs of animals after tail vein injection while a 
sizable subset of fibrosarcoma cells persist? These 
differences may reflect differential attack by natural 
killer cells or relative efficiencies of two different 
immuno-modulatory mechanisms operating in the lung 
as observed in other tumor systems in animal models 
(Glaves, 1980; Barlozzi et al., 1983; Kawaguchi and 
Nakamura, 1986; Ramani and Balkwill, 1988; Aslakson 
et al., 1991). One approach for addressing these 
differences is co-injection of LZ-CWR22R cells with 
fibrosarcoma cells tagged with a different histochemical 
marker gene (e.g., human placental alkaline 
phosphatase). This approach has been used by us to test 
two different oncogene-transformants of fibroblasts to 
demonstrate synergy between two genetically-different 
subpopulations (Lin et al., 1993). 
Overall, this LZ-CWR22R cell system is an ideal 
model of the human disease processes of progression 
and metastasis for severa1 reasons. First, this cell type 
was derived from a primary human tumor and, therefore, 
is not an already-metastaticly-selected cell 
subpopulation such as DU145, PC3 or LNCaP. Second, 
LZ-CWR22R cells metastasize to the three principal 
organs involved in the human disease beyond the 
prostate gland in both spontaneous and experimental 
metastasis model systems - Le., lung, liver, and bone. 
Third, the efficiency of selection of metastatic variants 
targeting the bone as spontaneous events offers promise 
for the first time of evaluating the gene regulatory events 
required to populate this unusual organ; the environment 
of bone must be very foreign to these transformed 
prostate epithelial cells. We are currently undertaking 
such studies (J.L. Holleran, J. Dennis and L.A. Culp, 
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unpublished data). Finally, the efficiency of outgrowth of 
liver micrometastases into overt metastases contrasts 
with the inefficiency of these events in lung and bone; 
therefore, these overt liver metastases should be 
evaluated with cell and molecular biological approaches 
to determine the basis for this efficiency. Reporter gene- 
tagging of these PCA cell systems offers us the highest 
degree of sensitivity for identifying the earliest events in 
micrometastasis formation and combining this biological 
system with ultra-sensitive gene evaluation techniques 
should identify organ-specific gene expression patterns. 
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